2025 World Conference on Lung Cancer: The 10 Most Noteworthy Studies

Lung Cancer Treatment Innovations – 2025

Lung cancer treatment is undergoing a clear evolution from single-agent approaches to rational combination strategies. Studies presented at IASLC 2025 highlight the consolidation of targeted therapy + chemotherapy synergy, the growing impact of ADCs, the establishment of perioperative immunotherapy as a standard in early-stage disease, and the emergence of new TKIs focused on CNS control. Some negative results (e.g., adjuvant crizotinib) are making clinical practice more evidence-driven and selective.

In summary, lung cancer management in 2025 is moving toward molecularly tailored, CNS-focused, and combination-driven strategies. Clinical decisions will increasingly integrate patient preferences, comorbidities, access/reimbursement, and real-world data, alongside dynamic biomarkers like ctDNA (MRD).

Study 1 — Iza-bren (izalontamab brengitecan) + Osimertinib

Why it matters: Achieving deep and durable first-line responses remains a critical need in EGFR-mutant NSCLC. The combination of the antibody–drug conjugate (ADC) iza-bren with osimertinib shows exceptionally high response and 12-month survival rates in early-phase data. This is a rare example illustrating the clinical potential of TKI + ADC synergy in targeted therapy.

📊 Quick Summary (Key Numbers)

• ORR: 100% (confirmed ORR 95%) — 2.5 mg/kg, D1D8, Q3W dose cohort
• 12-month PFS rate: 92.1% (median PFS: —)
• 12-month OS rate: 94.8% (median OS: —)
• Tolerability: Manageable safety profile; most common AEs were hematologic; low discontinuation rate

Note: Follow-up ~12–13 months; early-phase data—interpretation applies to the reported dose cohort.

🧱 Study Design and Population

• Phase: Phase 2 (NCT05880706)
• Population: EGFR-mutant, locally advanced / metastatic NSCLC
• Regimen: Iza-bren 2.5 mg/kg D1 & D8, Q3W + osimertinib (standard dose)
• Follow-up: Median for PFS ≈ 12.5 months; median for OS ≈ 12.8 months
• Sample size: Limited reporting in the presentation — results are dose-cohort–focused

📈 Results at a Glance

🧯 Safety and Tolerability

• The most frequent hematologic adverse events were reported (grades and rates were limited in the slides).
• Dose interruptions/discontinuations were infrequent; overall profile deemed manageable.
• No new safety signals were reported with concomitant osimertinib.

🧭 How to Interpret These Results

The ADC + TKI approach may extend response duration and reduce early progression compared with TKI alone. An ORR up to 100% and a 12-month PFS >92% suggest a biologically appealing strategy for patients with high tumor burden and/or risk of brain metastases in the first-line setting. That said, comparative phase 3 evidence is still required for routine adoption.

🚧 Limitations (Read with Caution)

• Early-phase / dose-cohort data — limited generalizability to broader populations.
• No control arm (single-arm) → be cautious when inferring effect size.
• Follow-up ~12–13 months; long-term OS/DOR not yet mature.
• Sample size and subgroup details were limited in the presentation.

🚀 Place in Practice and What’s Next

• For now, best considered within clinical trial settings; phase 3 confirmation is needed for routine use.
• Ongoing phase 3: NCT06838273 (China) — will clarify the combination’s potential to become a first-line standard.
• Future work should focus on brain metastasis subgroups and resistance biology (e.g., EGFR C797S, MET amplification).

Editor’s note: Content is based on IASLC 2025 congress presentation data; figures pertain to the reported dose cohort.

Study 2 — FLAURA2: Osimertinib + Chemotherapy (First Line)

Why it matters: In advanced EGFR-mutant NSCLC, osimertinib monotherapy has long been the first-line standard. Updated FLAURA2 data confirm that osimertinib + platinum/pemetrexed not only improves PFS but also provides a statistically significant and clinically meaningful OS benefit—reshaping first-choice algorithms in many centers.

📊 Quick Summary (Key Numbers)

• Median OS: Combination 47.5 months vs monotherapy 37.6 months → 23% reduction in risk of death
• PFS (previously reported): 38% reduction in risk of progression/death
• Safety: Manageable; no new signals with additional follow-up

Note: OS follow-up ~51.2 months; results are statistically significant and clinically meaningful.

🧱 Study Design and Intervention

• Phase: Phase 3 (NCT04035486)
• Population: EGFR-mutant (commonly Ex19del / L858R) advanced NSCLC
• Arms:
  • Combination: Osimertinib + platinum/pemetrexed induction → osimertinib + pemetrexed maintenance
  • Control: Osimertinib monotherapy
• Primary/secondary endpoints: PFS, OS, response rates, safety

📈 FLAURA2 by the Numbers

🧭 What Changes in Practice?

• Combination first-line therapy is being adopted as a new SOC in many centers.
• Provides rationale for a more intensive upfront approach in patients with high tumor burden, early progression risk, or brain metastasis likelihood.
• In real-world settings, chemo fitness (hematologic reserve, comorbidities) and patient preference are key determinants.

👥 Patient Selection — When to Choose Combination?

• Good performance status (ECOG 0–1)
• High tumor burden / need for rapid control
• High risk of brain metastases
• Adequate hematologic reserve, low comorbidity load
• Patient preference: willing to accept more intensive therapy for potential OS gain

Alternative: In frail patients or those unlikely to tolerate chemotherapy, monotherapy remains reasonable.

🧯 Safety and Management Tips

• Hematologic toxicity: manage neutropenia/anemia with dose delays, G-CSF, and supportive care
• Renal function & folate/B12 monitoring: pemetrexed prerequisites
• Follow-up intensity: closer monitoring during the first 3–4 months (CBCs, symptom checks)

🚧 Limitations and Open Questions

• Cost and access: economic burden / reimbursement considerations
• Need for real-world evidence in the elderly and frail population
• Resistance patterns: post-combination molecular resistance profile and next-line options

📝 Final Takeaway

FLAURA2 clearly demonstrates an OS advantage for osimertinib + chemotherapy in first-line EGFR-mutant NSCLC. The clinical impact is tangible: in eligible patients, the combination is increasingly becoming the default choice.

Study 3 — CheckMate 77T: Perioperative Nivolumab (resectable NSCLC)

Why it matters: In early-stage, surgery-eligible NSCLC, recurrence risk is high, and pre-/post-operative (perioperative) strategies shape long-term outcomes. CheckMate 77T, which evaluated neoadjuvant nivolumab + platinum-doublet chemotherapy followed by adjuvant nivolumab after surgery, not only prolonged event-free survival (EFS) but also increased pathologic complete response (pCR) and did not negatively impact health-related quality of life (HRQOL).

📊 Quick Summary (Key Numbers)

• EFS (median): Not reached with nivolumab vs 18.4 months with placebo
• pCR: Higher with nivolumab (synergy of neoadjuvant IO + chemo)
• HRQOL: Lower risk of deterioration, particularly in stage III N2 disease
• Safety: Overall manageable, consistent with expected class effects

Note: Patients with EGFR mutations or ALK rearrangements were excluded; the target population was adults with resectable NSCLC.

🧱 Study Design and Intervention

• Phase: Phase 3 (NCT04025879)
• Population: Resectable stage III N2 or non-N2 NSCLC (EGFR/ALK negative)
• Arms:
  • Experimental: Neoadjuvant nivolumab + platinum-doublet chemo → surgery → adjuvant nivolumab
  • Control: Neoadjuvant placebo + platinum-doublet chemo → surgery → adjuvant placebo
• Key endpoints: EFS, pCR/MPR, HRQOL (time to definitive deterioration, TTDD), safety

📈 CheckMate 77T at a Glance

🧭 What Do the HRQOL Findings Mean?

Maintaining HRQOL with neoadjuvant immunotherapy plus chemotherapy followed by adjuvant nivolumab supports the sustainability of perioperative IO strategies not only for oncologic outcomes but also for patient-reported outcomes. The delay in deterioration (longer TTDD), especially in stage III N2, is clinically meaningful.

🧯 Safety: Practical Tips

• Immune-related AEs: early recognition and algorithmic management for dermatitis, thyroiditis, hepatitis, pneumonitis
• Perioperative timing: ensure appropriate intervals between neoadjuvant cycles and surgery
• Multidisciplinary follow-up: close coordination with thoracic surgery, oncology, pulmonology, and anesthesia

🚀 Place in Clinical Practice

• Neoadjuvant nivolumab + chemo followed by adjuvant nivolumab has strengthened as a reasonable perioperative standard for resectable (EGFR/ALK-negative) NSCLC.
• Beyond EFS and pCR gains, preserved HRQOL supports adherence.
• Patient selection: surgery-eligible, no IO contraindications, manageable comorbidity profile.

Note: These data align with the FDA label; continue to monitor real-world evidence and longer-term OS maturity.

🚧 Limitations and Open Questions

• Long-term OS: longer follow-up may be needed to fully translate EFS into OS.
• Subgroup nuances: histology, PD-L1 level, and minimal residual disease (ctDNA) correlations matter.
• Real-world feasibility: surgical timing, pre-op work-up, and logistics vary across centers.

Study 4 — Taletrectinib (Ibtrozi): TRUST-I & TRUST-II

Why it matters: In ROS1-positive NSCLC, TKIs are effective, yet resistance and CNS spread remain major challenges. Taletrectinib, a ROS1-selective TKI with potential brain penetration, shows durable responses and encouraging CNS control signals in both treatment-naïve and T KI-pretreated populations.

📊 Quick Summary (Key Numbers)

• cORR (TKI-naïve): 85.2% (n = 54); median 20.5 months follow-up
• Median PFS / DOR (TKI-naïve): Not reached; longest observed PFS 31.6 months and ongoing
• cORR (TKI-pretreated): 61.7% (n = 47)
• CNS/intracranial responses: Response rate 66.7% in patients with brain metastases
• Safety: Overall manageable; most adverse events were transient

Note: Derived from updated interim analyses of two phase 2 studies.

🧱 Study Design and Population

• Design: Phase 2, single-arm/multicenter (TRUST-I and TRUST-II)
• Population: Advanced/metastatic ROS1-positive NSCLC; TKI-naïve and TKI-pretreated cohorts
• Prior therapy: Separate analyses — no prior ROS1 TKI vs ≥1 prior ROS1 TKI
• Endpoints: cORR (primary), DOR, PFS, OS, safety; intracranial activity sub-analyses

📈 TRUST-I / II at a Glance

🧠 CNS Activity: Clinical Relevance

In ROS1+ NSCLC, brain metastases are common and drive long-term control. Taletrectinib’s intracranial response rate of 66.7% suggests CNS penetration and a profile consistent with potential systemic disease control.

🧯 Safety and Tolerability

• Overall profile is favorable and manageable.
• Drug-related AEs were mostly transient and manageable with dose modification/interruptions.
• Tolerability appears maintained even in those with prior TKI exposure.

🚀 Place in Practice and Patient Selection

• In first-line TKI-naïve ROS1+ patients, high cORR supports strong candidacy.
• In TKI-pretreated patients, meaningful activity → a rational option post-resistance.
• With CNS risk/presence, intracranial efficacy is clinically attractive.
• Head-to-head comparisons and sequential strategies versus other ROS1 TKIs are needed.

🚧 Limitations and Open Questions

• Single-arm, phase 2 design → limited inference on comparative efficacy.
• Follow-up not yet mature; median PFS/DOR not reached.
• Further molecular work is needed on the resistance spectrum and post-treatment sequencing.

Editor’s note: Clinical decisions should incorporate access/reimbursement, patient preferences, center experience, and multidisciplinary tumor board discussion.

Study 5 — Zidesamtinib (NVL-520): ARROS-1

Why it matters: In ROS1-positive NSCLC, TKI resistance (especially G2032R) and CNS spread hinder durable disease control. Zidesamtinib is a next-generation TKI that is ROS1-selective, TRK-sparing, and capable of CNS penetration. Phase 1/2 ARROS-1 data indicate durable responses and good tolerability despite multiple prior ROS1 TKIs.

📊 Quick Summary (Key Numbers)

• ORR (after 1–4 ROS1 TKIs): 44%
• ORR (after only 1 prior ROS1 TKI; n=55): 51%
• DOR maintenance rate (months 6/12/18): up to 93%
• Median PFS: Approximately ~24 months (≈ 2 years)
• G2032R resistance mutation: durable activity
• CNS efficacy: Intracranial responses observed in patients with brain metastases
• Safety: Overall well tolerated with low dose-reduction and discontinuation rates

Note: Interim data from dose-escalation/expansion cohorts; direct cross-trial comparisons are hypothesis-generating only.

🧱 Study Design and Population

• Design: Phase 1/2 (ARROS-1); dose escalation + expansion cohorts
• Population: Advanced/metastatic ROS1-positive NSCLC, including multiple prior ROS1 TKI lines
• Endpoints: ORR (primary), DOR, PFS, OS, safety; G2032R and CNS subgroup analyses

📈 ARROS-1 at a Glance

🧠 CNS Activity: Clinical Relevance

The intracranial responses with zidesamtinib suggest it could serve as a bridge or alternative option in sequential treatment for ROS1+ NSCLC with brain metastases. Effective CNS control can strongly influence PFS/OS.

🧯 Safety and Management

• Overall profile: Well tolerated with low dose-reduction/discontinuation rates
• TRK sparing: May potentially reduce off-target neurologic AEs
• Close monitoring: Headache, dizziness, GI symptoms, and LFTs (per institutional protocols)

🚀 Place in Practice and Strategy

• Strong option after progression on 1 prior TKI; rational choice in G2032R-positive cases.
• Attractive where CNS risk/presence exists due to intracranial activity.
• Sequencing: Before or after repotrectinib/taletrectinib; awaiting head-to-head data.

Editor’s note: Claims of numerical superiority must be interpreted cautiously due to cross-trial differences; direct comparisons and real-world data will be instructive.

🚧 Limitations and Open Questions

• Early-phase / single arm: limited inference for comparative efficacy
• Follow-up: Some endpoints not yet mature (e.g., median DOR)
• Resistance biology: Post-zidesamtinib mutation patterns and optimal sequencing strategy

Study 6 — NADIM ADJUVANT: Nivolumab + Chemotherapy (Adjuvant)

Why it matters: After complete (R0) resection, recurrence remains a key challenge in NSCLC. The adjuvant nivolumab + platinum-based chemotherapy strategy aims to reduce the biologic risk of relapse beyond a “pathologically clean” status. NADIM ADJUVANT provides strong signals of improved disease-free survival (DFS).

📊 Quick Summary (Key Numbers)

• 24-month DFS: 77.7% (nivo+chemo) vs 67.9% (chemo)
• 36-month DFS: 73.3% (nivo+chemo) vs 59.9% (chemo)
• Cancer-specific DFS (sensitivity): Statistically significant
• Safety: Manageable; consistent with prior experiences for IO/chemo

Note: Population: completely resected stage IB–IIIA NSCLC.

🧱 Study Design and Intervention

• Phase: Phase 3 (NCT04564157)
• Population: Completely resected stage IB–IIIA NSCLC
• Arms:
  • Experimental: Adjuvant nivolumab + platinum-based chemo
  • Control: Adjuvant chemotherapy alone
• Endpoints: DFS (primary), cancer-specific DFS, OS, safety

📈 NADIM ADJUVANT at a Glance

🧭 What Do These Results Mean?

In completely resected stage IB–IIIA NSCLC, adjuvant nivolumab + chemotherapy shows the potential to substantially reduce relapse in the first 2–3 years. The persistent separation in DFS curves could serve as an early indicator for eventual OS benefit (final OS maturity pending).

🧯 Safety: Practical Tips

• Immune-related AEs: screen for thyroid dysfunction, hepatitis, and pneumonitis; intervene early based on symptoms
• Chemo toxicities: neutropenia, anemia, nausea — supportive care and dose-delay algorithms
• Follow-up: imaging every 3–6 months; ctDNA (if available) for MRD to detect relapse early

🚀 Place in Practice and Patient Selection

• Reasonable option for patients with R0 resection, ECOG 0–1, and no contraindications to IO.
• Particularly valuable in higher-risk cases (stage II–IIIA, nodal involvement, larger tumors).
• Multidisciplinary planning: thoracic surgery, oncology, and radiology for cohesive follow-up.

🚧 Limitations and Open Questions

• OS maturity: Longer follow-up is needed to confirm full translation of DFS into overall survival.
• Biomarkers: more data on PD-L1 levels, ctDNA-based MRD, and subgroup benefits are needed.
• Real-world feasibility: Tolerability and completion rates may vary in comorbid/older populations.

Study 7 — HARMONi: Ivonescimab (PD-1/VEGF bispecific) + Carboplatin/Pemetrexed

Why it matters: Progression after third-generation EGFR TKI (e.g., osimertinib) is a key clinical gap in EGFR-mutated NSCLC. Ivonescimab is a bispecific antibody combining PD-1 blockade and anti-VEGF activity in a single molecule. Phase 3 HARMONi data show that adding ivonescimab to chemotherapy provides meaningful benefits, particularly for PFS and intracranial control.

📊 Quick Summary (Key Numbers)

• PFS (median): 6.8 mo (ivonescimab+chemo) vs 4.4 mo (placebo+chemo); HR 0.52, p<0.0001
• OS (median): 16.8 mo vs 14.0 mo; HR 0.79 — positive trend (nominally significant in Western patients)
• Intracranial PFS: HR 0.34 (brain-metastasis subgroup)
• ORR: 45% vs 34%
• Safety: Manageable; any-grade TRAE: 95.0% vs 93.1%

Note: All patients had progressed after a 3rd-gen TKI; platinum/pemetrexed backbones were compared.

🧱 Study Design and Population

• Phase: Phase 3 (NCT06396065)
• Population: Post–third-gen EGFR TKI advanced/metastatic EGFRm NSCLC with progression
• Arms:
  • Experimental: Ivonescimab + carboplatin/pemetrexed (induction → pemetrexed ± ivonescimab maintenance)
  • Control: Placebo + carboplatin/pemetrexed (induction → pemetrexed + placebo maintenance)
• Endpoints: PFS (primary), OS, ORR, intracranial PFS, safety

📈 HARMONi at a Glance

🧭 What Do These Results Mean?

After TKI progression, adding the combined anti-PD-1 + anti-VEGF effect to chemotherapy confers advantages in early disease control (PFS) and CNS management. The positive OS trend—including nominal significance in Western subgroups—supports the signal; final interpretation awaits mature OS data.

👥 Patient Selection — When to Use Ivonescimab + Chemo?

• Post–3rd-gen TKI progression (especially early progression profile)
• Brain metastases present or at high risk (intracranial benefit)
• ECOG 0–1, adequate hematologic reserve, chemo-eligible
• No contraindication to anti-VEGF (bleeding risk, uncontrolled hypertension, etc.)

🧯 Safety: Practical Management

• Immune-related AEs: dermatitis, thyroiditis, hepatitis, pneumonitis — early screening and algorithmic management
• Anti-VEGF-related: hypertension, proteinuria, bleeding risk — close BP/urine protein monitoring
• Chemo toxicities: neutropenia, anemia, fatigue — G-CSF, dose delays, supportive care

🚧 Limitations and Open Questions

• OS maturity: Longer follow-up required; subgroup heterogeneity should be clarified.
• Biomarkers: Relationships with PD-L1 level, angiogenic signatures, and resistance biology need exploration.
• Sequencing: No head-to-head data versus other IO/anti-VEGF combinations post-TKI.

Editor’s note: Apply these findings alongside patient preferences, comorbidities, and reimbursement context.

Study 8 — ACROSS 2: Aumolertinib + Carboplatin/Pemetrexed (1st Line)

Why it matters: In EGFR-mutated NSCLC, tumor suppressor gene (TSG) co-mutations (especially TP53) can be associated with earlier resistance and shorter PFS on TKI monotherapy. ACROSS 2 tests whether adding platinum/pemetrexed to aumolertinib improves outcomes in this “high-risk” biology.

📊 Quick Summary (Key Numbers)

• Median PFS: 19.8 mo (aumolertinib + chemo) vs 16.5 mo (aumolertinib)
• ORR: 70.4% (combination) vs 67.2% (monotherapy)
• Subgroups: Clear PFS benefit in TP53 co-mutation and EGFR exon 19 deletion
• Safety: TEAEs more frequent with combination, but overall manageable

Note: 1st-line advanced/metastatic EGFRm NSCLC; TSG co-mut populations are considered high risk.

🧱 Study Design and Intervention

• Phase: Phase 3 (NCT04500717)
• Population: Advanced/metastatic EGFRm NSCLC (including defined TSG co-mutation subgroups)
• Arms:
  • Combination: Aumolertinib + carboplatin/pemetrexed (induction → aumolertinib ± pemetrexed maintenance)
  • Control: Aumolertinib monotherapy
• Endpoints: PFS (primary), ORR, DOR, OS, safety; TSG co-mutation subgroup analyses

📈 ACROSS 2 at a Glance

🧭 What Do These Results Mean?

In TSG co-mutated EGFRm cases, single-agent TKI tends to fail earlier. Choosing TKI + chemo up front is rational to slow tumor biology and achieve longer PFS. Concomitant chemo may suppress microscopic resistant clones, reducing early escape patterns.

🧯 Safety: Practical Tips

• Hematologic AEs: neutropenia/anemia; dose delays, G-CSF, supportive care
• Pemetrexed prerequisites: folate/B12 and renal function monitoring
• Aumolertinib class effects: rash, diarrhea; early symptom-based interventions

👥 Patient Selection — When to Combine?

• TP53 co-mutation or other TSG alterations (STK11/KEAP1, per institutional practice)
• High tumor burden or predicted early progression risk
• ECOG 0–1 with adequate hematologic reserve

Alternative: In comorbid/frail profiles, monotherapy may be chosen with close PFS surveillance.

🚧 Limitations and Open Questions

• AE burden: Combination toxicity may impact completion rates in real-world settings.
• Sequencing: Optimal order of 2L options after progression (e.g., other TKIs, IO + chemo) remains unclear.
• Biomarkers: Magnitude of benefit should be parsed by TSG subtype (e.g., TP53 variant class).

Study 9 — IDeate-Lung01: Ifinatamab Deruxtecan (I-DXd)

Why it matters: In relapsed extensive-stage small cell lung cancer (SCLC), effective second-line options are limited. I-DXd is a B7-H3–targeted antibody–drug conjugate (ADC) that stands out for its potential to induce rapid responses and a high disease control rate.

📊 Quick Summary (Key Numbers)

• ORR (confirmed): 48.2% (n = 137; 12 mg/kg)
• DCR: 87.6%
• TTR (median): 1.4 months — rapid response
• DOR (median): 5.3 months
• PFS (median): 4.9 months
• OS (median): 10.3 months

Note: Clinical benefit was observed regardless of platinum sensitivity and line of therapy; a signal for intracranial activity was reported.

🧱 Study Design and Population

• Phase: Phase 2, single arm (NCT05280470)
• Population: Previously treated extensive-stage SCLC
• Intervention: I-DXd 12 mg/kg (q3w)
• Endpoints: ORR (primary), DOR, PFS, OS, safety; intracranial subgroup analyses

📈 I-DXd by the Numbers

🧭 What Do These Results Mean?

48% ORR with a 1.4-month time to response may provide early symptomatic relief in patients with high tumor burden. PFS 4.9 months and OS 10.3 months represent a competitive profile versus current 2L options, notably with benefit observed irrespective of platinum sensitivity.

🧯 Safety and Management

• TRAE (any grade): 89.8%; Grade ≥3: 36.5% — manageable
• ADC class warnings: Early education and low threshold evaluation for interstitial lung disease/pneumonitis
• Supportive care: Dose delays/reductions for hematologic toxicity, G-CSF; antiemetic prophylaxis

🚀 Place in Clinical Practice and Patient Selection

• In 2L+ extensive-stage SCLC with need for rapid symptom control, a strong option
• Consider in patients with CNS involvement given reported intracranial activity signal
• Close monitoring and education for high-risk AEs (especially pneumonitis) are essential

🚧 Limitations and Open Questions

• Single arm/early phase: Randomized data are needed for comparative superiority
• OS maturity: More granular analyses by subgroups (platinum-sensitive/resistant, CNS involvement) are needed
• Sequencing: Optimal post-ADC strategies (topo1-ADC → chemo/IO combinations, etc.) should be clarified

Study 10 — ALCHEMIST: Adjuvant Crizotinib (ALK+; resected NSCLC)

Why it matters: Whether adjuvant targeted therapy can reduce recurrence in early-stage, completely resected ALK-positive NSCLC has been a long-standing question. The phase 3 ALCHEMIST trial showed that crizotinib did not improve DFS or OS versus observation, providing important negative evidence against this adjuvant strategy.

📊 Quick Summary (Key Numbers)

• Follow-up (median): 58.3 months
• DFS: no benefit — HR 1.06, P=0.86
• OS: not statistically significant — HR 0.49, P=0.26
• Subgroups: No significant benefit by sex, stage, or postoperative RT
• Toxicity: Similar to advanced-disease profile; >25% experienced treatment discontinuation

🧱 Study Design and Population

• Phase: Phase 3 (NCT02194738)
• Population: Resected ALK-positive NSCLC (early/intermediate stage; adjuvant setting)
• Arms: Adjuvant crizotinib vs observation
• Endpoints: Disease-free survival (DFS), OS, safety

📈 ALCHEMIST by the Numbers

🧭 What Do These Results Mean?

In early-stage ALK+ NSCLC, adjuvant crizotinib does not reduce recurrence or prolong survival. The substantial discontinuation rate further questions tolerability in the adjuvant context. Thus, crizotinib is not a standard adjuvant approach. For adjuvant targeted strategies, randomized data with other agents and long-term outcomes should be monitored closely.

🧯 Safety: Practical Notes

• Class effects: GI symptoms, liver enzyme elevations, visual disturbances, QT prolongation — symptom tolerance is lower in the adjuvant setting.
• Monitoring: LFTs, ECG (QTc), close symptom-based follow-up; early dose modifications

🚧 Limitations and Open Questions

• Agent-specific outcome: The negative finding may not generalize to the entire ALK TKI class; pharmacology differs among agents.
• Subgroup nuances: Detailed analyses by stage, nodal status, and interactions with adjuvant chemo/RT are relevant.
• Future direction: Await randomized data with more potent/modern ALK TKIs and MRD/ctDNA-guided approaches in the adjuvant setting.

Practice Impact — Quick Decision Box

Bottom line: In 2025, lung cancer management is shaped by combinations, CNS control, and dynamic biomarkers. Integrating these findings with center experience, patient preference, and reimbursement context can help align with current standards and maximize patient benefit.

📚 References

1. Iza-bren + Osimertinib (Phase 2)
   Zhou F, Wang Q, Wang H, et al. Phase II study... IASLC WCLC 2025; Abstract 2114.
2. Osimertinib + Chemotherapy (FLAURA2)
   Planchard D, Jänne PA, Kobayashi K, et al. Final OS... IASLC WCLC 2025; Abstract 1956.
   N Engl J Med. 2023;389(21):1935-1948. doi:10.1056/NEJMoa2306434.
   FDA Approval
3. Perioperative Nivolumab (CheckMate 77T)
   Spicer JD, Pulla MP, Cascone T, et al. PROs with perioperative nivolumab... IASLC WCLC 2025; Abstract 3005.
   Cascone T, Awad MM, Spicer JD, et al. N Engl J Med. 2024;390(19):1756-1769. doi:10.1056/NEJM0a2311926.
   FDA Approval
4. Taletrectinib (TRUST-I/II)
   NCT04919811, NCT04395677.
5. Zidesamtinib (ARROS-1)
   Drilon AE, Cho BC, Lin JJ, et al. ARROS-1 pivotal data... IASLC WCLC 2025; Abstract 4540.
   NCT05118789
6. Adjuvant Nivolumab + Chemotherapy (NADIM ADJUVANT)
   Provencio M, Bernabé R, Nadal E, et al. Phase III... IASLC WCLC 2025; Abstract PL03.07.
7. Ivonescimab + Chemotherapy (HARMONi)
   Goldman JW, Passaro A, Laskin J, et al. Phase 3 HARMONi... IASLC WCLC 2025; Abstract 4808.
   NCT06396065
8. Aumolertinib + Chemotherapy (ACROSS 2)
   Wang J. ACROSS 2 phase III... IASLC WCLC 2025; Abstract 2205.
   NCT04500717
9. Ifinatamab Deruxtecan (I-DXd; IDeate-Lung01)
   Ahn M-J, Johnson ML, Paz-Ares L, et al. Phase 2 IDeate-Lung01... IASLC WCLC 2025; Abstract OA06.03.
   NCT06203210
10. Adjuvant Crizotinib Shows No Benefit in ALK+ NSCLC
    Gerber DE, Wang Y, Lange CJ, et al. Phase 3 trial of crizotinib vs observation... IASLC WCLC 2025; Abstract 2559.
    NCT02194738